Markley John D. Jr. has reported a transaction involving shares of InterDigital, Inc., acquiring 7.55 shares as of October 28, 2026. This acquisition is part of a broader trend in executive compensation practices within the patent industry.
Markley is a director at InterDigital, a company known for its work in the patent space. The recent filing, accession number 0001628280-26-068412, highlights the nature of executive compensation through stock units, which can influence how shareholders view company leadership.
The filing indicates that the shares were acquired through restricted stock units linked to dividend equivalents. These equivalents accrue when cash dividends are paid on InterDigital's common stock.
This transaction may affect perceptions among shareholders and other stakeholders regarding executive compensation and alignment with shareholder interests. As the patent industry evolves, competitors may also consider adjusting their compensation structures in light of such disclosures.
The filing does not say what happens next.
Following this transaction, Markley now holds a total of 11,750.9542 shares of InterDigital, Inc.'s common stock. This increase in ownership reflects the ongoing accumulation of shares through the company's compensation structure, which is designed to align executive interests with those of shareholders.
The filing notes that the shares were acquired at a transaction price of $0, indicating that they were granted as part of a compensation package rather than purchased outright. This approach is common in executive compensation, particularly in industries where stock performance is closely tied to company success.
Additionally, the filing specifies that the restricted stock units were received pursuant to dividend equivalents credited on unvested restricted stock units previously granted to Markley. This mechanism ensures that executives benefit from cash dividends paid on the company's common stock, further incentivizing long-term investment in the company.
It is important to note that the filing does not provide any information regarding future transactions or changes in Markley's role within the company, nor does it address potential impacts on the company's stock performance or market perception following this acquisition.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






